Liquidia Corporation Stock price

Equities

LQDA

US53635D2027

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
14.75 USD -2.12% Intraday chart for Liquidia Corporation -9.17% +22.61%
Sales 2024 * 58.49M Sales 2025 * 162M Capitalization 1.12B
Net income 2024 * -84M Net income 2025 * -38M EV / Sales 2024 * 18.8 x
Net cash position 2024 * 22.77M Net Debt 2025 * 99.53M EV / Sales 2025 * 7.54 x
P/E ratio 2024 *
-13.2 x
P/E ratio 2025 *
-29.6 x
Employees 145
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.58%
More Fundamentals * Assessed data
Dynamic Chart
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing MT
Liquidia Corporation(NasdaqCM:LQDA) added to S&P Pharmaceuticals Select Industry Index CI
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating MT
Transcript : Liquidia Corporation, 2023 Earnings Call, Mar 13, 2024
Liquidia's 2023 Net Loss Widens, Revenue Increases -- Shares Advance Pre-Bell MT
Liquidia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certain Stock Units of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Warrants of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Options of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Common Stock of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia MT
US FDA Yutrepia Review Delay 'Yet Another Setback' For Liquidia, Wedbush Says MT
Liquidia Says Yutrepia Inhalation Powder to Treat Hypertension Still Under Review by US FDA MT
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder CI
Liquidia Says United Therapeutics Filed for Dismissal of Certain Claims in Patent Infringement Litigation MT
More news
1 day-2.12%
1 week-9.17%
Current month+4.17%
1 month+2.54%
3 months+22.20%
6 months+132.28%
Current year+22.61%
More quotes
1 week
14.26
Extreme 14.26
16.92
1 month
13.00
Extreme 13
16.99
Current year
11.11
Extreme 11.11
16.99
1 year
5.71
Extreme 5.71
16.99
3 years
2.25
Extreme 2.25
16.99
5 years
2.25
Extreme 2.25
16.99
10 years
2.25
Extreme 2.25
38.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 20-11-17
Director of Finance/CFO 48 20-11-29
Chief Tech/Sci/R&D Officer 50 22-07-17
Members of the board TitleAgeSince
Director/Board Member 72 20-06-27
Director/Board Member 69 20-06-27
Chief Executive Officer 62 20-11-17
More insiders
Date Price Change Volume
24-03-28 14.75 -2.12% 2,048,845
24-03-27 15.07 -5.34% 1,503,407
24-03-26 15.92 +1.60% 654,644
24-03-25 15.67 -6.34% 1,171,163
24-03-22 16.73 +3.02% 672,238

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
14.75 USD
Average target price
23.86 USD
Spread / Average Target
+61.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Liquidia Corporation - Nasdaq